Attendee search 

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

maintect GmbH was founded 2018 in collaboration with Mainz University Medical Center Germany by ophthalmological scientists.
maintect is developing an innovative antibody treatment for a new target instead of the well-known VEGF in wAMD (wet age-related-macular-degeneration, one of the most frequent causes of blindness). This new antibody will help the patients who don’t benefit from anti-VEGF treatment and all others. maintect applied already for patent in several countries. Combination with anti-VEGF is also an option. In parallel, the company is developing a companion diagnostic kit using lateral flow assays for anti-VEGF treatment in wAMD. This test will determine which patients will benefit most from the new treatment and will facilitate the market entrance. Furthermore, the company is interested in contract research and collaborations in building diagnostic kits.

Avanc Pharmaceutical Co., Ltd (Avanc Pharma or the Company), a wholly-owned subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd, focuses on innovative drug R&D, production and distribution and has a long-term commitment to nervous system, oncology, perioperative drugs and pediatric drugs.

Opera CRO is an international contract research organization (CRO) with offices in Italy (Genoa), in Switzerland (Geneva) and in Romania (Timisoara) that has been managing clinical trials since 1995. In particular, we performed several clinical studies with medical devices, medical drugs and food supplements in many different therapeutic areas.

We offer the possibility of conducting clinical trials in different countries in Eastern Europe, with reduced costs and faster times, or in other European and non-European countries (Italy, France, Switzerland, Germany etc..). Additionally, we offer specific support for the compliance of medical device registrations of the CE marking to the new European regulation. Recently, Opera CRO was acquired by the Tigermed group, the largest CRO in Asia with over 5000 employees and 100 offices. This partnership offers the opportunity to perform clinical trials in China and in the rest of Asia and access that vast market.
The list of our current studies can be found on ClinicalTrial.gov (specifying Opera CRO for Europe, Tigermed for Asia); further information is available on our website: www.operacro.com.

EpicentRx is an immuno-oncology company whose focus is to identify and develop less toxic and more effective immunotherapy-based anti-cancer treatments that are active not only as single agents, but that also sensitize tumors to the cytotoxic effects of chemotherapy, radiation and immune checkpoint blockade. EpicentRx's lead program is among a portfolio of novel dinitroazetidine-based drugs that downregulate CD47 – SIRPα to alter the tumor microenvironment and optimize immune responses as well as normalize the tumor vasculature for better drug and oxygen delivery, and has been tested in several clinical trials including an ongoing Phase 3 study in SCLC. The company is also advancing multiple programs through its smart virus AdAPT platform, including three anti-SARS-CoV-2 vaccines, a TGF-beta "trap" starting Phase 1, and various personalized cancer vaccines that have shown to be effective in both chemotherapy and immune resistant tumors. For more information regarding EpicentRx, go to: http://www.epicentrx.com.

We are a corporate finance firm committed to advancing the field of Healthcare through advisory,and investments.

We advise and buy-side and sell side corporates and Family offices on investment in Healthcare & life Sciences across Switzerland, Europe and the US.

Who We Are

An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition